Sheldon Okada

Sheldon Okada currently serves as the Vice President of Business & Commercial Strategy, bringing over two decades of experience in the biopharmaceutical sector. His career is marked by significant roles in commercial and financial planning, particularly in the development and patient access to transformative therapies. Previously, Okada was the Senior Director of Commercial Strategy at Forty Seven Inc., where he established the commercial function and supported development strategies, including early launch preparations for a leading oncology program. Prior to that, he spent 14 years at Gilead Sciences, where his responsibilities grew within the Commercial Strategy and Financial Planning groups. During his tenure at Gilead, he played a key role in the launch of four FDA-approved drugs and supported various development programs in areas such as infectious diseases, liver disease, and inflammation. Okada holds a Master of Science in Chemistry from the California Institute of Technology and a Bachelor of Arts in Molecular and Cell Biology from the University of California, Berkeley.